| PO Number | Paper Number | First Name | Last Name | Paper Title |
| P01 | 1 | Farnaz | Araghi | The emerging role of T cells in pemphigus vulgaris: a systematic review |
| P02 | 2 | Farnaz | Araghi | TEN/SJS-like lupus erythematosus presentation complicated by COVID-19 |
| P03 | 3 | Farnaz | Araghi | COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience |
| P04 | 8 | Meropi | Karakioulaki | Treatment of a patient with severe dystrophic epidermolysis bullosa with Beremagene Geperpavec (B-VEC) gene therapy |
| P05 | 10 | Marney | White | Characterizing Disability, Quality of Life, and Remission Status in Autoimmune Blistering Diseases |
| P06 | 11 | REY TRISTAN JOSHUA | UNAY | Pemphigoid Gestationis in Pregnancy Decoded |
| P07 | 15 | Florentina-Silvia | Delli | Gene therapy for skin bullous diseases – where are we? |
| P08 | 16 | Harrison | Loftus | Psoriasis and Depression: The Role of Inflammation |
| P09 | 17 | Harrison | Loftus | Pemphigus Vulgaris: Patient-Centered Clinical Pearls |
| P10 | 18 | Eirini | Kyrmanidou | Netherthon Syndrome: therapeutic approach with dupilumab, our experience |
| P11 | 19 | Stephanie | Goletz | Diagnosis of anti-p200 pemphigoid |
| P12 | 20 | Sierra | Parkinson | Nonbullous pemphigoid mimicking arthropod bite reactions in a patient with previously controlled classic bullous pemphigoid |
| P13 | 24 | Roberto | Maglie | Tralokinumab as a novel effective therapy for bullous pemphigoid |
| P14 | 25 | ANTHI | CHATZIKYRIAKIDOU | Association of FOXP3 gene variant rs3761548 with pemphigus vulgaris: a pilot study |
| P15 | 28 | Dario | Didona | Safety, tolerability, and pharmacokinetics of TPM203, a tolerizing Topas particle mixture in pemphigus vulgaris: preliminary results from a phase 1, first in man study (EudraCT Number: 2019-001727-12) |
| P16 | 30 | Anikka Mae Crystal | Ollet | A Case of Psoriasis and Pemphigus Foliaceous in a 55-year-old Filipino |
| P17 | 31 | Virginia Evdokia | Pappa | Bullous pemphigoid in a patient with psoriasis and acquired reactive perforating collagenosis |
| P18 | 33 | EFTHYMIA | KARAGIANNOPOULOU | ORAL MUCOSAL TELANGIECTASIAS AS THE ONLY CLINICAL SIGN OF A PRE-CLINICAL CREST SYNDROME CASE |
| P19 | 34 | Marney | White | Gender and Race/Ethnicity in Autoimmune Blistering Diseases: Do Women and Racial/Ethnic Minorities Experience a Disproportionate Burden of Disease? |
| P20 | 38 | Masahiro | Tsutsumi | The improved keratinocyte dissociation assay using desmoglein-knockout keratinocytes |
| P21 | 39 | Qijun | Wang | Efficacy and safety of different rituximab dosage regimens in pemphigus patients: A multicenter retrospective study |
| P22 | 41 | Manuela | Pigors | Laminin β4 as autoantigen of anti-p200 pemphigoid: pathogenicity and potential interaction with laminin α3 and γ2 |
| P23 | 42 | Sabrina | Patzelt | Topical C5aR1 inhibition reduced clinical lesions in a preclinical model of mucous membrane pemphigoid |
| P24 | 43 | Eleni | Paschou | A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis. |
| P25 | 44 | Chrysostomos | Goulas | Development of bullous pemphigoid during treatment with benralizumab for eosinophilic asthma |
| P26 | 48 | Suying | Feng | Retrospective Analysis of Clinical and Immunoserological Features of Anti-p200 Pemphigoid in a Chinese National Medical Center |
| P27 | 49 | EFTERPI | ZAFIRIOU | Effective treatment of Bullous Pemphigoid in a patient with nephrotic syndrome with Mycophanolate Mofetil (Case Presentation) |
| P28 | 50 | Kossara | Drenovska | Comedonic pemphigus erythematosus: does it exist? |
| P29 | 51 | Dario | Didona | Hard as a rock: a case of massive rupioid psoriasis |
| P30 | 53 | Nina | Kokkonen | The use of dipeptidyl peptidase-4 inhibitors modifies the interplay between the cutaneous cytokines, eosinophils and epitope spectra of anti-BP180 IgG autoantibodies in bullous pemphigoid |
| P31 | 54 | EFTERPI | ZAFIRIOU | Topical Baricitinib in Alopecia Areata: A Case Report |
| P32 | 55 | Charlotte | Kiehne | Facilitation of diagnosis of pemphigoid diseases with serum autoantibodies against the dermal side of salt-split skin by indirect immunofluorescence microscopy |
| P33 | 58 | MA. BERNADETTE | SEDANO | Navigating the Complexities of Rupioid Psoriasis: A Successful Treatment Journey |
| P34 | 59 | Effimia | Stergiadou | Correlation between mucous membrane pemphigoid and malignant transformation in the oral mucosa. |
| P35 | 60 | Martin | Shahid | HLA-DQB1 typing among Bulgarian patients with dermatitis herpetiformis |
| P36 | 61 | Anne-Lise | Strandmoe | Analysis of the circulating immune profile in pemphigus vulgaris reveals distinct patterns related to disease state |
| P37 | 62 | MA. BERNADETTE | SEDANO | Charting New Territory: Chronic Bullous Disease of Childhood in Adolescence |
| P38 | 63 | NIKOLETTA | TSAVALOPOULOU | Immune checkpoint inhibitor induced peristomal localized bullous pemphigoid |
| P39 | 64 | Ayrton Michael | Gonzales | A CASE OF DIFFUSE CUTANEOUS BULLOUS MASTOCYTOSIS IN AN 8-MONTH-OLD FEMALE SEEN AT SOUTHERN ISABELA MEDICAL CENTER |
| P40 | 65 | EFTERPI | ZAFIRIOU | Drug- induced bullous pemphigoid in a patient with treatment resistant psoriasis successfully treated with Ustekinumab (case report) |
| P41 | 66 | PANAGIOTIS | MARINOS | Localized form of oral lichen planus (OLP) in of the upper lip and gingiva. A new subtype? |
| P42 | 71 | Anna | Vatalachou | When trichoscopy is not enough: a single-center study of clinical and trichoscopic characteristics of hair disorders demanding histopathologic confirmation of the diagnosis. |
| P43 | 72 | Ezdean | Alkurdi | The Patient’s Perspective: Evaluation of Bullous Pemphigoid Information on Social Media Platforms |
| P44 | 73 | Elia | Valeva | Mucous membrane pemphigoid associated with malignancy |
| P45 | 74 | Eirini | Kyrmanidou | The Hair Diseases Outpatient Clinic of Papageorgiou Hospital: an epidemiologic study |
| P46 | 75 | Hana | Jedlickova | Mucous membrane pemphigoid diagnostics with western blot analysis |
| P47 | 76 | Eleni | Stroumpi | Refractory and life threatening pemphigus vulgaris in an elderly female patient |
| P48 | 78 | Bianca | Opelka | Epitope-dependent autoantibody-mediated skin inflammation in pemphigoid |
| P49 | 79 | Anastasia | Tsitlakidou | Antirituximab antibodies – do they play any role in the treatment response and course of pemphigus? |
| P50 | 80 | Anissa | ZAOUAK | Nail involvement in pemphigus: a prospective clinical and dermoscopic study |
| P51 | 81 | ARGYROULA | PAPADOPOULOU | CASE OF A PATIENT WITH PEMPHIGUS VULGARIS TREATED WITH RITUXIMAB WITH SPECIAL COURSE DURING THE COVID-19 ERA |
| P52 | 82 | Efthymia | Soura | Demographic data and decision-making processes in patients with Bullous Pemphigoid receiving dupilumab treatment |
| P53 | 83 | Nikolaos | Chaitidis | Clinical and Epidemiological Characteristics of Gliptin-Induced Bullous Pemphigoid: The Greek Experience. |
| P54 | 84 | Maria Polina | Konstantinou | Epidemiology of Pemphigus in Greece: A 5-year, multicenter Study |
| P55 | 85 | Anastasia | Tsitlakidou | Advantages of rituximab therapy early in the course of pemphigus – data from northern Greece |
| P56 | 86 | Georgia | Pappa | CASTLEMAN DISEASE AFTER A 10-YEAR PERIOD OF BULLOUS DISEASE: PEMPHIGUS VULGARIS OR PARANEOPLASTIC PEMPHIGUS IN DISGUISE? |
| P57 | 87 | Agoritsa | Gravani | Bullous pemphigoid in Greece: Epidemiological evidence and impact of diabetes mellitus and gliptin use on adjuvant treatment administration – a five-year study |
| P58 | 90 | VASILIKI | PAPADOPOULOU | ERYTHRODERMIC PSORIASIS: COMPLETE REMISSION AFTER ADMINISTRATION OF BIMEKIZUMAB |
| P59 | 91 | Aikaterini | Patsatsi | Association of Serum Levels of Total-IgE Autoantibodies With Disease Activity and Severity in Patients with Bullous Pemphigoid |
| P60 | 92 | Aleksandra | Lesiak | Epidermolysis Bullosa Acquisita in a 2-Year-Old Girl: A Case Report |
